

**MEDICAL DATA VISION CO., LTD (3902 JP)**

NO CHANGE IN MEDIUM-TERM TARGET ASSUMING GROWTH AFTER UPFRONT INVESTMENTS MADE IN FY24

**EXECUTIVE SUMMARY****➤ Revision to FY24 Guidance**

MDV revised down its full-year FY24 guidance (discussed in more details on p.5) given the Q3 result [Q1~Q3 gross profit [GP] of ¥3,055mil (-12.8% YoY), operating loss of -¥140mil (vs FY23 Q3 OP of ¥1,111mil) on sales of ¥4,125mil (-8.1% YoY)], due to (1) the delay to the onboarding of the firm's cloud-based health check system solution Alpha Salus as the debugging process continued through to September, and (2) a delay in mobilising potential users of the new content (no-contact vital sensing for cats) for MDV's personal health management app Karteco, as the planned large-scale advertising campaign was pushed back following a delay in the launch of the content. The firm had already assumed higher costs and upfront investments for FY24 hence the decline in profits due to: (1) higher COGS (+¥491mil) associated with Karteco and other cloud-based services, (2) higher personnel costs (+¥351mil), and (3) a +¥434mil increase in advertisement and promotion costs on Karteco.

**➤ Will MDV be able to achieve the medium-term plan [MTP] target in FY25?**

Yes. MTP's targets remain unchanged [FY25 RP of ¥2,500mil+ (CAGR of +16.1%+, on FY22 as the base year) on sales of ¥10,000mil (CAGR of +16.7%+)] solely from organic growth of its existing businesses. The firm proactively spent the aforementioned upfront investments in FY24 to capture growth in FY25. Issues that dragged sales down in FY24 have already been remedied.

**➤ Shareholders Return**

MDV's shareholders return policy offers an annual dividend pay-out ratio of 20%+. The firm is guiding for FY24 annual dividend of ¥6.5/share (unchanged from FY23) and generates a dividend pay-out ratio of 138.0% based on the revised FY24 EPS forecast of ¥4.71.

**MDV (3902 JP): Share Information**

Market Cap (¥mil)		17,400	Market Cap (\$mil)		116	
22-day Average Trading Volume (¥mil)		151	22-day Average Trading Volume (\$mil)		1.0	
Share performance (%)	3902	TOPIX	Earnings Summary (¥mil, %)	FY22	FY23	FY24CE
Share price (¥, 4 Dec 2024)	437.00	2,740.60	Sales	6,104	6,419	6,600
3mo	-16.6	+4.1	OP	1,758	1,770	510
6mo	-17.1	-1.7	OPM (%)	28.8	27.6	7.7
YTD	-33.3	+15.8	EBITDA	1,820	1,818	570*
1yr	-37.3	+16.0	Financial Leverage (X)	1.3	1.4	1.4*
5yrs	-54.9	+60.9	Net D/E Ratio (X)	-0.6	-0.7	-0.7*
Per-share and Valuations	3902	TOPIX	FCF	42	1,179	N/A
EPS (¥, FY24 CE)	4.71	179.35				
DPS (¥, FY24 CE)	6.5	N/A	Shareholder Return Summary	FY22	FY23	FY24CE
BPS (¥, June-24)	102.3	1970.45	Dividend (¥)	6.0	6.5	6.5
FCFPS (¥, FY24EST)	N/A	N/A	Dividend Payout (%)	26.3	25.4	138.0
Forward PER	92.8	15.28	Dividend Yield (%)	N/A	N/A	1.5
PBR (x)	4.3	1.39	DOE (%)	6.2	5.3	6.4*
PCFR (x)	N/A	N/A	Treasury Shares (%)	N/A	N/A	4.5
EV/EBITDA	14,182	N/A	ROE (%)	24.7	23.0	22.0*

Source: Nippon-IBR based on data on Bloomberg and Toyo Keizai / \*Nippon-IBR estimates

## FY24 Q3 RESULTS SUMMARY

Medical Data Vision [MDV] reported FY24 (Dec year-end) Q3 gross profit [GP] of ¥3,055mil (-12.8% YoY), an operating loss of -¥140mil (vs FY23 Q3 OP of ¥1,111mil) on sales of ¥4,125mil (-8.1% YoY). Given the Q3 performance, the firm revised down its full-year forecasts due as (1) the onboarding of the Alpha Salus, the cloud-based health check system solution, was delayed due to a debugging issue which continued to September, and (2) a set-back in launching the planned large-scale advertising campaign to mobilise users of the new content – no-contact vital sensing contents for cats – for Karteco, MDV's personal health management app, as the content launch was delayed. Furthermore, to achieve the medium-term target, the planned investments to boost manpower, the launch of the TV advert of Karteco and R&D will squeeze FY24 OP.

The gross profit margin [GPM] continues to contract, declining from 78.0% in FY23 Q1~Q3, to 74.1% in FY24 Q1~Q3. FY24 Q1~Q3 COGS rose +¥85mil / +8.6% YoY to ¥1,071mil, of which +¥24mil YoY was for higher costs for the fee-paying MDV Act service and its personal health record [PHR] service Karteco.

In Q3 alone, the company reported an operating loss of -¥166mil (vs OP of ¥392mil in FY23 Q3 alone) on sales of ¥1,345mil (-9.4% YoY / -3.4% QoQ), due to higher advertisement costs of Karteco (+¥235mil YoY) – part of the budgeted ¥434mil FY24 advertisement cost to promote Karteco. The impact from greater advertising is evident in the surge in numbers of downloads [DLs] of the app, which increased from 62,105 DLs in FY24 Q1, 167,698 DLs in FY24 Q2 and to 630,369 DLs in FY24 Q3 vs FY24 target of 780,000 DLs. Therefore, MDV will likely spend the remaining budget in the Q4 to ensure the firm achieves the full-year DL target. The ultimate goal is to boost fee-paying users of the Karteco app.

In addition, Karteco services used by corporates, such as Sony Biz Network Corporation [SBNC, Unlisted], as of Q3 has started generating revenue. MDV also released Karteco workwell, an app linked to SBNC's attendance management system.

MDV (3902 JP): Earnings Summary (Cumulative)							
¥mil	FY23			FY24			
	1H	Q3	FY	Q1	1H	Q3	YoY (%)
Sales	3,002	4,487	6,419	1,388	2,780	4,125	-8.1
GP	2,345	3,501	5,031	1,045	2,061	3,055	-12.8
GPM (%)	78.1	78.0	78.4	75.3	74.1	74.1	-3.9ppt
SG&A	1,625	2,390	3,260	991	2,034	3,195	33.7
SG&A / Sales (%)	54.1	53.3	50.8	71.4	73.2	77.5	+24.2ppt
OP	719	1,111	1,770	53	26	-140	N/A
OPM (%)	24.0	24.8	27.6	3.9	1.0	-3.4	-28.2ppt
RP	700	1,063	1,700	22	-32	-229	N/A
RPM (%)	23.3	23.7	26.5	1.6	-1.2	-5.6	-29.3ppt
NP*	445	659	979	-15	-86	-314	N/A
Dividend (¥)	N/A	N/A	6.5	N/A	N/A	N/A	N/A

Source: Nippon-IBR based on MDV's earnings results materials  
\* NP attributed to the parent's shareholders

## PERFORMANCE BY SEGMENT

MDV's business portfolio is largely divided into two segments:

### 1. Data Network Services

The segment FY24 Q1~Q3 GP fell -53.2% YoY to ¥225mil on sales of ¥900mil (-14.6% YoY). During the 9 months running up to Q3, MDV generated semi-annual stock (recurring) revenue of ¥646mil (-1.4% YoY) as the numbers of fee-paying hospitals that use the firm's cloud-based MRV Act rose. The Q1~Q3 flow revenue declined -44.4% YoY to ¥88mil due to a removal of part of sales from flow revenue.

Data Network Service New Sales Breakdown (Cumulative)								
¥mil	FY23				FY24			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	YoY (%)
Data Network Total	388	723	1,053	1,462	332	625	900	-14.6
Flow Revenue (initial fees)	72	133	158	256	48	50	88	-44.4
Recurring Revenue (monthly subscription fees)	230	442	655	875	220	428	646	-1.4
New Businesses (subsidiaries)	86	146	239	330	63	146	161	-32.8
Karteco					0	0	4	N/A
Other services	147	271	402	521	127	249	389	-3.4

Source: Nippon-IBR Based on MDV's earnings results materials

Data Network Service New Sales Breakdown (Quarterly)									
¥mil	FY23				FY24				
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	YoY (%)	QoQ (%)
Data Network Total	388	334	330	409	332	293	274	-17.0	-6.4
Flow Revenue (initial fees)	72	61	24	97	48	1	37	52.1	1832.8*
Recurring Revenue (monthly subscription fees)	230	212	212	220	220	208	217	2.2	4.2
New Businesses (subsidiaries)	86	60	93	90	63	82	14	-83.9	-81.9
Karteco					0	0	4	N/A	N/A
Other services	147	124	130	118	127	122	139	6.5	14.1

Source: Nippon-IBR Based on MDV's earnings results materials  
NB: \* Sales of System B Alpha is split into Flow and Stock revenues from FY24 Q3.

Data Network Services comprise: (1) MDV Act, (2) Alpha Salus, and (3) Karteco:

**MDV Act:** The segment saw a steady increase in the number of fee-paying customers for MDV Act, which rose from 652 hospitals in FY24 Q1, to 674 hospitals in FY24 Q2 and then hit 683 hospitals in FY24 Q3. So far, MDV has focused on encouraging existing on-premises EVE users to switch to the cloud-based MDV Act. Given the transition is now almost complete, the firm aims to cultivate new customers. Fee-paying services were first launched in FY23 Q2. The FY24 Q1~Q3, sales of MDV Act's fee-paying services increased +106.6% YoY – well ahead of the pace +78.4% YoY planned for FY24.

Management remains confident that shift to fee-paying customers will steadily continue and boost sales. Furthermore, the release of new functions on MDV Act will encourage existing customers to take up the fee-paying services and also bring in new customers. In FY24, MDV aims to realise a +78.4% YoY rise in “stock-based” (recurring) sales of fee-paying MDV Act from the 638 hospitals (those which started using the fee-paying services in FY23), and by mobilising more customers to its fee-paying services.

**Alpha Salus:** Onboarding of the health check system recommenced in FY23 Q4, which improved the number of health check facilities that have introduced MDV's system to 100 facilities. However, this fell to 97 facilities in FY24 Q2 and then declined further to 87 facilities in Q3 due to existing customers switching to systems offered by other companies. Additionally, MDV had to suspend the promotion and onboarding of new customers due to a new bug found in the system during the nine months.

Due to these obstacles, management acknowledge that it is difficult to achieve the target of 161 health check facilities taking up the system in FY24. However, now that the debugging issue has been dealt with, the firm's focus will be on how to onboard the 20 customers which are currently included in order backlogs.

**Karteco:** One of the segment's potential growth drivers is Karteco, a service ultimately used by consumers to monitor their health records online or via an app. MDV launched a large-scale promotion campaign to boost the number of downloads [DLs] for the service in Q3 by spending advertisement cost of ¥235mil. The firm's FY24 Karteco sales target

of ¥520mil (¥0mil in FY24 1H) will be unlikely achieved; while MDV expects to increase the number of fee-paying app users by first launching a bio-sensing contents for cats and dogs, the launch of the version for cats has been delayed to FY24 Q4. On the other hand, Karteco's corporate service was launched and deployed by Sony Biz Networks, which generated ¥4mil revenue in Q3.

## 2. Data Utilisation Services

Segment GP for FY24 Q1~Q3 was ¥2,507mil (-7.1% YoY) on sales of ¥2,836mil (-6.4% YoY). Sales for the 9-month period of ad hoc services declined -9.1% YoY to ¥2,157mil, primarily due to the launch of high fee-paying ad hoc services only made a small contribution in Q3. MDV reckons this dip in its medical data survey analysis services sales is temporary while the new sales and marketing staff members are undergoing training. Once the new staff training completes, more senior staff can be fully allocated to sales and marketing activities.

In Q3 alone, sales of ad hoc services were ¥706mil (-12.8% YoY / -5.7% QoQ) with the segment GPM flat YoY. On the other hand, MDV analyzer saw a steady increase in sales which increased +3.3% YoY to ¥678mil during the 9 months period, thanks to those users opting to have MDV analyzer for multiple services, such as DPC data set (number of patients, prescription dosage, number of days prescribed etc) and that of insurance patients' data, which improved ARPU. In Q3 alone, sales of MDV analyzer landed ¥225mil (+5.6% YoY / -1.0% QoQ).

Data Utilisation Service Segment: Sales Breakdown by Service (Cumulative)								
(¥mil)	FY23				FY24			
	Q1	1H	Q3	FY	Q1	1H	Q3	YoY (%)
Data Utilisation Total	1,022	2,007	3,030	4,434	928	1,904	2,836	-6.4
MDV analyzer	217	443	657	865	225	453	678	3.3
Medical data survey analysis	805	1,563	2,373	3,569	702	1,451	2,157	-9.1

Source: Nippon-IBR Based on MDV's earnings results materials

Data Utilisation Service Segment: Sales Breakdown by Service (Quarterly)										
(¥mil)	FY23				FY24				YoY (%)	QoQ (%)
	Q1	Q2	Q3	Q4	Q1	Q2	Q3			
Data Utilisation Total	1,022	984	1,023	1,403	928	976	931	-9.0	-4.6	
MDV analyzer	217	226	213	208	225	227	225	5.6	-1.0	
Medical data survey analysis	805	758	810	1,195	702	748	706	-12.8	-5.7	

Source: Nippon-IBR Based on MDV's earnings results materials

## FY2024 OUTLOOK

Given the weaker than expected Q1~Q3 performance, MDV revised down its FY24 guidance from FY24 OP of ¥1,630mil (-8.0% YoY) and RP of ¥1,540mil (-9.4% YoY) on sales of ¥8,000mil (+24.6% YoY) to OP of ¥510mil (-71.2% YoY) and RP of ¥390mil (-77.1% YoY) on sales of ¥6,600mil (+2.8% YoY).

MDV states that although the Q1~Q3 performance reflected the negative impact to sales from (1) the delay in onboarding the Alpha Salus services as the debugging process took longer than expected, and (2) a delay in a large advertising campaign following the delay in the launch of an app. The campaign will likely commence from Q4 onwards. The downward revision in FY24 sales (-¥1,400mil) comprises (1) delays in the onboarding of Alpha Salus (approx. -¥650mil), (2) the delay in the launch of the Karteco app (-¥500mil), and (3) the decline in Ad Hoc services in the Data Utilisation Services segment (-¥200mil).

On the other hands, the firm had already assumed an increase in costs hence guiding for a decline in profit growth due to: (1) higher COGS (+¥491mil) associated with Karteco and cloud-based services, (2) higher personnel costs (+¥351mil), and (3) a +¥434mil increase in advertisement and promotion costs on Karteco, for FY24.

MDV (3902 JP): Earnings Summary and Guidance							
(¥mil)	FY23		FY24				
	1H	FY	1H	FY CE	YoY (%)	New FY CE	YoY (%)
Sales	3,002	6,419	2,780	8,000	24.6	6,600	2.8
GP	2,345	5,031	2,061	N/A	N/A	N/A	N/A
GPM (%)	78.1	78.4	74.1	N/A	N/A	N/A	N/A
SG&A	1,625	3,260	2,034	N/A	N/A	N/A	N/A
SG&A / Sales (%)	54.1	50.8	73.2	N/A	N/A	N/A	N/A
OP	719	1,770	26	1,630	-8.0	510	-71.2
OPM (%)	24.0	27.6	1.0	20.4	-7.2ppt	7.7	-19.9ppt
RP	700	1,700	-32	1,540	-9.4	390	-77.1
RPM (%)	23.3	26.5	-1.2	19.3	-7.2ppt	5.9	-20.6ppt
NP*	445	979	-86	1,000	2.1	180	-81.6
Dividend (¥)	N/A	6.5	N/A	6.5	0.0	6.5	0.0

Source: Nippon-IBR based on MDV's earnings results materials  
\* NP attributed to the parent's shareholders

## PROGRESS ON MEDIUM-TERM MANAGEMENT PLAN (FY23-FY25)

FY24 is the second year of MDV's three-year medium-term management plan. Although FY23 and FY24 Q1~Q3 earnings fell short of the firm's initial guidance, primarily due to the weak performance of its subsidiaries as well as aforementioned delay in onboarding the Alpha Salus system and the launch of the Karteco app, the firm still views its medium-term targets for FY25 RP of ¥2,500mil<sup>+</sup> (CAGR of +16.1%+, on FY22 as the base year) on sales of ¥10,000mil (CAGR of +16.7%+) – solely from organic growth of the firm's existing businesses – to be achievable. The firm proactively made upfront investments in FY24 to capture the growth from FY25 onwards.

To achieve these goals, MDV will need to see:

1. An increase in Data Utilisation Service marketing staff to capture more users,
2. Sequential launches of fee-paying functions on MDV Act,
3. A rise in the number of health check facilities that use the Alpha Salus system, and
4. Karteco downloads to hits 780,000 in FY24 and then to reach 5.3mil in FY25.

## SHAREHOLDER RETURNS

MDV's shareholders return policy offers an annual dividend pay-out ratio of 20%+. In FY24, MDV plans to pay a dividend of ¥6.5/share, no change from FY23, which generates a dividend pay-out ratio of 138.0% based on the revised FY24 EPS of ¥4.71.

The firm also implemented share buybacks of ¥589mil in FY20, ¥889mil in FY21, and ¥862mil in FY22 which saw total shareholder returns of 104.5%, 101.8%, 125.4%, respectively. The firm did not buy back any shares in FY23.

As of June 2024, 4.5% of shares outstanding remained as treasury shares. For the medium-term plan, MDV has not yet detailed the shareholder return policy.

## GENERAL DISCLAIMER AND COPYRIGHT

This report has been commissioned by Medical Data Vision Co., Ltd. [MDV] (the Sponsor) and prepared and issued by Nippon Investment Bespoke Research UK Ltd (Nippon-IBR), in consideration of a fee payable by MDV. Fees are paid on delivery of the report in cash without recourse. Nippon-IBR may seek additional fees for the provision of follow-up research reports and associated IR services for the Sponsor but does not get remunerated for any investment banking services. We never take payment in stock, options, or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however Nippon-IBR does not guarantee the accuracy or completeness of this report and has not sought for this information to be independently verified. Opinions contained in this report represent those of the Nippon-IBR analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Nippon-IBR shall not be liable for any direct, indirect, or consequential losses, loss of profits, damages, costs, or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Nippon-IBR's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Nippon-IBR has a restrictive policy relating to personal dealing and conflicts of interest. It does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees, and contractors of Nippon-IBR may have a position in any or related securities mentioned in this report, subject to its policies on personal dealing and conflicts of interest.

**Copyright:** Copyright 2024 Nippon Investment Bespoke Research UK Ltd.

For further enquiry, please contact:

Nippon Investment Bespoke Research UK Ltd  
118 Pall Mall  
London SW1Y 5EA  
TEL: +44 (0)20 7993 2583  
Email: [enquiries@nippon-ibr.com](mailto:enquiries@nippon-ibr.com)



Research Beyond Horizons  
Japanese Equity Specialist

*Nippon Investment Bespoke Research UK Ltd (formerly known as NIB Research UK Ltd.) is registered in England and Wales (9100028) and is authorised and regulated by the Financial Conduct Authority (FRN: 928332).*